Anhui Fengyuan Pharmaceutical Co Ltd Capital Reinvestment Ratio
Anhui Fengyuan Pharmaceutical Co Ltd capital reinvestment ratio. Anhui Fengyuan Pharmaceutical Co Ltd (000153) has a Capital Reinvestment Ratio of 0.46x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥69.15 Million) in capital expenditures (CN¥32.02 Million). See Anhui Fengyuan Pharmaceutical Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Anhui Fengyuan Pharmaceutical Co Ltd (1999–2025)
Capital reinvestment ratio of Anhui Fengyuan Pharmaceutical Co Ltd from 1999 to 2025. This chart tracks Anhui Fengyuan Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 24 annual periods. See Anhui Fengyuan Pharmaceutical Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Anhui Fengyuan Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (1999–2025)
Anhui Fengyuan Pharmaceutical Co Ltd capital reinvestment ratio by year from 1999 to 2025. For the full cash flow conversion analysis, see cash efficiency ratio of Anhui Fengyuan Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.85x | CN¥119.30 Million | CN¥220.61 Million | ▲ +62.1% |
| 2024 | 1.14x | CN¥126.24 Million | CN¥144.02 Million | ▲ +91.1% |
| 2023 | 0.60x | CN¥254.75 Million | CN¥152.12 Million | ▲ +221.3% |
| 2022 | 0.19x | CN¥439.99 Million | CN¥81.76 Million | ▼ -71.9% |
| 2021 | 0.66x | CN¥237.88 Million | CN¥157.36 Million | ▲ +1.5% |
| 2020 | 0.65x | CN¥292.75 Million | CN¥190.74 Million | ▼ -70.4% |
| 2019 | 2.20x | CN¥66.21 Million | CN¥145.62 Million | ▲ +507.0% |
| 2018 | 0.36x | CN¥233.59 Million | CN¥84.63 Million | ▼ -60.4% |
| 2017 | 0.92x | CN¥52.40 Million | CN¥47.99 Million | ▲ +223.2% |
| 2016 | 0.28x | CN¥78.21 Million | CN¥22.17 Million | ▼ -74.4% |
| 2015 | 1.11x | CN¥45.50 Million | CN¥50.33 Million | ▼ -93.4% |
| 2014 | 16.73x | CN¥10.51 Million | CN¥175.86 Million | ▲ +703.5% |
| 2012 | 2.08x | CN¥45.65 Million | CN¥95.06 Million | ▲ +64.1% |
| 2011 | 1.27x | CN¥55.06 Million | CN¥69.86 Million | ▼ -22.2% |
| 2010 | 1.63x | CN¥55.04 Million | CN¥89.75 Million | ▼ -29.0% |
| 2009 | 2.30x | CN¥32.41 Million | CN¥74.42 Million | ▲ +262.3% |
| 2008 | 0.63x | CN¥49.82 Million | CN¥31.58 Million | ▼ -0.4% |
| 2007 | 0.64x | CN¥55.26 Million | CN¥35.18 Million | ▼ -83.1% |
| 2006 | 3.77x | CN¥36.27 Million | CN¥136.67 Million | ▲ +268.4% |
| 2005 | 1.02x | CN¥34.88 Million | CN¥35.68 Million | ▼ -88.3% |
| 2002 | 8.73x | CN¥10.48 Million | CN¥91.40 Million | ▲ +8.1% |
| 2001 | 8.07x | CN¥23.57 Million | CN¥190.24 Million | ▲ +77.3% |
| 2000 | 4.55x | CN¥25.88 Million | CN¥117.82 Million | ▲ +0.5% |
| 1999 | 4.53x | CN¥1.01 Million | CN¥4.59 Million | — |